EverPoint Asset Management’s Rocket Pharmaceuticals RCKT Stock Holding History

EverPoint Asset Management’s Portfolio RCKT Stock Details RCKT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$1.44M	Sell	58,932 -66,068	-53%	-$1.89M	0.03%	349
2016 Q3	$4.74M	Sell	125,000 -13,882	-10%	-$437K	0.09%	255
2016 Q2	$4.13M	Sell	138,882 -36,850	-21%	-$1.3M	0.08%	246
2016 Q1	$5.2M	Buy	175,732 +2,687	+2%	+$80.6K	0.1%	216
2015 Q4	$7.84M	Sell	173,045 -33,205	-16%	-$1.45M	0.16%	172
2015 Q3	$7.75M	Buy	+206,250	New	+$9.47M	0.2%	149

Other funds holding RCKT

RCP

Rho Capital Partners New York $20.4M AUM

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

SAM

Senzar Asset Management New York $34.7M AUM 0.56% 1-Year Est. Return

EverPoint Asset Management's RCKT Position: Q4 2016 in Review

EverPoint Asset Management reduced its Rocket Pharmaceuticals (RCKT) stake by 53% in Q4 2016, selling an estimated $1.89M and leaving 58,932 shares worth $1.44M. The position accounts for 0.03% of the portfolio, ranked #349.

EverPoint Asset Management first reported a position in RCKT in Q3 2015 and has held it in 6 quarters since. The position peaked at $7.84M in Q4 2015. 82 funds tracked by Wall St. Rank hold RCKT as of Q4 2016.

EverPoint Asset Management held 58,932 shares of Rocket Pharmaceuticals worth $1.44M as of Q4 2016.
EverPoint Asset Management sold 66,068 Rocket Pharmaceuticals shares in Q4 2016, an estimated $1.89M.
Rocket Pharmaceuticals made up 0.03% of EverPoint Asset Management's portfolio in Q4 2016, its #349 holding.
EverPoint Asset Management first reported a position in Rocket Pharmaceuticals in Q3 2015 and has held it in 6 quarters since.
EverPoint Asset Management's Rocket Pharmaceuticals position peaked at $7.84M in Q4 2015.
82 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q4 2016.

Based on EverPoint Asset Management's 13F filing for Q4 2016, filed 14 Feb 2017.